Abstract
After the introduction of HAART in the late 1990s, there were dramatic reductions in HIVrelated neurological disorders such as dementia, CNS lymphoma and cerebral toxoplasmosis [1]. However, minor neurocognitive disorders are still detected in a high proportion of patients receiving antiretrovirals, even if HIV RNA levels are suppressed below 50 copies/ml in plasma [2,3]. HIV-associated neurocognitive disorders are defined by asymptomatic neurocognitive impairment, minor neurocognitive disorders and HIV-associated dementia. These disorders are identified either by clinical diagnosis and/or neurocognitive testing. In some studies, samples of cerebrospinal fluid (CSF) have been tested for HIV RNA and plasma PK levels of antiretrovirals. There is a background incidence of neurological disorders in the general population [4,5], and there may be other confounding factors such as recreational drug use, psychiatric illness, a lcohol abuse/use and hepatitis B or C infection [6].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.